Publications by authors named "Reza Emadi"

The combination of methylprednisolone (MPDL) and curcumin (CUR) for treating rheumatoid arthritis (RA) offers several therapeutic advantages. This synergy allows for a reduction in the dosage of methylprednisolone, minimizing potential side effects associated with long-term steroid use while maintaining or enhancing the treatment's effectiveness. The objective of this study is to prepare drug carriers for MPDL and CUR aimed at treating RA, utilizing Freund's Complete Adjuvant-induced arthritic rat model (AIA).

View Article and Find Full Text PDF

Emerging as a promising drug target for Alzheimer's disease (AD) therapy, glycogen synthase kinase 3β (GSK-3β) has garnered attention. This study sought to rigorously scrutinize a compendium of natural compounds retrieved from the ZINC database through pharmacodynamic experiments, employing a 1 H-indazole-3-carboxamide (INDZ) scaffold, to identify compounds capable of inhibiting the GSK-3β protein. Utilizing a multi-step approach, the study involved pharmacophore analysis, followed by molecular docking to select five promising ligands for further investigation.

View Article and Find Full Text PDF

Alzheimer's disease (AD) is a neurological condition currently with 47 million people suffering from it globally. AD might have many reasons such as genetic issues, environmental factors, and Aβ accumulation, which is the biomarker of the disease. Since the primary reason is unknown, there is no targeted treatment at the moment, but ongoing research aims to slow its progression by managing amyloid-beta peptide production rather than symptomatic improvement.

View Article and Find Full Text PDF

C-N cross-coupling bond formation reactions have become valuable approaches to synthesizing anilines and their derivatives, known as important chemical compounds. Recent developments in this field have focused on versatile catalysts, simple operation methods, and green reaction conditions. This review article presents an overview of C-N cross-coupling reactions in pharmaceutical compound synthesis reports.

View Article and Find Full Text PDF

Recombinant human erythropoietin (rHuEPO) as a glycoprotein growth factor has been considered a biological drug for treatment of anemic patients with chronic renal failure or who receive cancer chemotherapy. Biological activity and circulation time are 2 parameters that are important to achieve EPO's efficacy. Previous efforts for increasing EPO's efficacy have focused on glycosylation modification via adding more sialic acid antenna and generates more negative charged protein.

View Article and Find Full Text PDF